Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Abcellera Biologics Inc (NQ: ABCL )

4.840 -0.010 (-0.21%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 854,100
Open 4.870
Bid (Size) 4.790 (7)
Ask (Size) 4.990 (10)
Prev. Close 4.850
Today's Range 4.790 - 4.960
52wk Range 3.870 - 11.47
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Micro/Small Cap Companies Using AI In Drug Discovery Up 35% In November
The AI method is up to 250 times more efficient than the traditional method of drug discovery. reducing timelines for drug discovery, increasing accuracy of efficacy and safety predictions. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AbCellera to Present at the Piper Sandler 35th Annual Healthcare Conference on November 30, 2023
From AbCellera Biologics Inc.
Via Business Wire

Performance

YTD
-49.00%
-49.00%
1 Month
+10.00%
+10.00%
3 Month
-12.95%
-12.95%
6 Month
-32.40%
-32.40%
1 Year
-56.55%
-56.55%

More News

Read More
AbCellera Presents New Data on Two T-Cell Engager Programs at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
Earnings Preview: AbCellera Biologics
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
AbCellera Biologics (ABCL) Q3 2023 Earnings Call Transcript
Via The Motley Fool
Topics Earnings
Exposures Financial
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AbCellera Reports Q3 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision Antibody Drug Conjugates in Oncology
From Prelude Therapeutics, Inc.; AbCellera
Via GlobeNewswire
AbCellera to Present at the Jefferies London Healthcare Conference on November 14, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Third Quarter 2023 Financial Results on November 2, 2023
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Two T-Cell Engager Presentations at SITC 2023
From AbCellera Biologics Inc.
Via Business Wire
Argenx's 28% Surge & Promising Product Propel Investor Confidence
Via MarketBeat
AbCellera Expands Multi-Target Antibody Discovery Collaboration with Regeneron
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces Collaboration with Incyte to Accelerate the Discovery and Development of Therapeutic Antibodies in Oncology
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Is Still A Buy Despite Dropping Royalties: Analyst On Long-Term Prospects
Via Benzinga
3 AI Stocks You’ll Regret Not Buying Soon
Via InvestorPlace
Why ResMed Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Apple, Fortinet, Microchip Technology And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
AbCellera Biologics (ABCL) Q2 2023 Earnings Call Transcript
Via The Motley Fool
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
AbCellera Reports Q2 2023 Business Results
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces that the U.S. Patent Trial and Appeal Board Has Denied Berkeley Lights’ Request for Rehearing
From AbCellera Biologics Inc.
Via Business Wire
Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.